A robust workforce, flourishing clinical trials, broad patient registries, and consensus treatment protocols contribute to improvements for the subspecialty
Search results for: polyarticular JIA
What Adult Rheumatologists Need to Know about Juvenile Arthritis
How to recognize distinctions between pediatric and adult arthritis
Growing Up Confident with Juvenile Idiopathic Arthritis
While juvenile arthritis can cause joint damage and limit function, rheumatologists strongly encourage children with JIA to live normal lives.
Patient Fact Sheet: Juvenile Idiopathic Arthritis
Several types of arthritis fall under the JIA heading. This inflammation begins before patients reach the age of 16 years, and may involve one or many joints and cause other symptoms such as fevers, rash, and eye inflammation.
Drug Updates
Information on New Approvals and Medication Safety
Juvenile Idiopathic Arthritis
Patient Fact Sheet
Pharmacokinetic Modeling & Efficacy Extrapolation: FDA Takes New Approaches to Drug Approvals
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
FDA Approves New Biosimilar for Adult & Pediatric Arthritis
This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.
FDA Provides 2020 Rheumatology Drug Update
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
The 2020 ACR Review Course: Key Issues Rheumatologists Face
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.